Aditya Bardia, MD

Conference Coverage

Datopotamab Deruxtecan for Metastatic Hormone Receptor-Positive, HER2-Negative Breast Cancer

10/25/2023

Aditya Bardia, MD, discusses results from the TROPION-Breast01 trial comparing datopotamab deruxtecan with chemotherapy for patients with inoperable or metastatic hormone receptor-positive, HER2-negative breast cancer who have previously...

Aditya Bardia, MD, discusses...

10/25/2023

Oncology

Videos

Addition of Ribociclib to Nonsteroidal Aromatase Inhibitor Benefits Broad Range of Patients With HR-Positive, HER2-Negative Early Breast Cancer

11/02/2023

Aditya Bardia , MD;

Aditya Bardia, MD, discusses results from a subgroup analysis of the phase 3 NATALEE study comparing invasive disease-free survival (iDFS) across a broad range of patients with HR-positive, HER2-negative early breast cancer treated with...

Aditya Bardia, MD, discusses...

11/02/2023

Oncology

Conference Coverage

Datopotamab Deruxtecan for Patients With Previously Treated, Inoperable, or Metastatic HR-Positive, HER2-Negative Breast Cancer

12/07/2023

Aditya Bardia , MD;

Aditya Bardia, MD, MPH, discussed results from the TROPION-Breast01 trial comparing datopotamab deruxtecan, a TROP-2 directed antibody drug conjugate, with standard chemotherapy in endocrine-resistant metastatic breast cancer.

Aditya Bardia, MD, MPH,...

12/07/2023

Oncology